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Abstract
Non-homologous end joining (NHEJ) is a major pathway for the repair of DNA double strand break (DSBs) with incompatible
DNA ends, which are often generated by ionizing irradiation. In vitro reconstitution studies have indicated that NHEJ of
incompatible DNA ends requires not only the core steps of synapsis and ligation, employing KU80/DNA-PKcs and LIG4, but
also additional DNA end processing steps, such as DNA end resection by Artemis and gap-filling by POLl and POLm.I t
seems that DNA end processing steps are important for joining of incompatible DNA ends rather than compatible ends.
Despite the fact that DNA end processing is important for incompatible DNA end joining in vitro, the role of DNA processing
in NHEJ of incompatible DSBs in vivo has not yet been demonstrated. Here we investigated the in vivo roles of proteins
implicated in each step of NHEJ using an assay in which NHEJ of incompatible DNA ends on chromosomal DNA can be
assessed in living human cells. siRNA- or inhibitor-mediated impairment of factors in each NHEJ step resulted in a reduction
in joining efficiency. Strikingly, stronger effects were observed when DNA end resection and ligation protein functions were
impaired. Disruption of synapsis by KU80 and DNA-PKcs impairment, or the disruption of gap filling by POLl and POLm
depletion, resulted in higher levels of microhomology-mediated joining. The present study indicates that DNA end resection
and ligation factors are critical for the efficient joining of incompatible ends in vivo, further emphasizing the importance of
synapsis and gap-filling factors in preventing illegitimate joining.
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Introduction
Non-homologous end joining (NHEJ) is a system that repairs
DNA double strand breaks (DSB) by joining two broken DNA
ends without requiring long stretches of homology, while
homologous recombination repair (HRR) joins two broken DNA
ends by using long (.100 bp) stretches of nucleotide homology
[1,2,3]. In NHEJ, a complex consisting of the KU70/KU80
heterodimer and DNA-PKcs mediates the synapsis of two broken
DNA ends and is followed by a ligation reaction performed by
LIG4/XRCC4/XLF. NHEJ of compatible DNA ends requires
synapsis and ligation factors in reconstitution systems, in which
purified proteins and naked DNAs are reacted in vitro. Thus, these
synapsis and ligation factors are defined as the core factors of
NHEJ [1,3,4,5]. The roles of synapsis and ligation factors in NHEJ
have also been examined in vivo and it was found that the depletion
of these factors reduces the efficiency of NHEJ, supporting the in
vitro findings. Lack of synapsis factors prompts micro-homology–
mediated joining, an alternative mode of NHEJ that does not
require synapsis factors [6,7,8,9].
Other factors involved in NHEJ include DNA end resection
and/or gap-filling proteins that process the DNA ends to be
joined. Pathological and physiological DSBs, such as those
generated by ionizing radiation (IR), often leave incompatible
DNA ends that require such processing before joining [1,4,10].
Therefore, DNA end resection and gap-filling are likely to be
additional but critical steps for NHEJ of DSBs in vivo. So far, the
molecular processes of DNA end resection and gap-filling have
been exclusively investigated using reconstitution systems in vitro.
Artemis, a DNA nuclease, [11], and two DNA polymerases (POLl
and POLm) [12,13] were implicated in end resection and gap
filling, respectively. However, whether these proteins contribute to
NHEJ repair of DSBs in vivo remains unknown due to the lack of
appropriate cell-based assay systems in which the function of DNA
end processing factors in NHEJ can be monitored.
In the present study, we investigated the in vivo roles of NHEJ
factors involved in synapsis, DNA end resection, gap-filling or
ligation by using an assay that we recently developed in which
NHEJ against chromosomal DSBs with incompatible DNA ends
can be assessed in living human cells [14]. In this system, DSBs
were generated by I-SceI endonuclease, which results in
incompatible DNA ends that require DNA end resection and
gap filling in order to be joined. The efficiency of repair was
evaluated by FACS analysis of eGFP protein produced from the
joined products. Modes for joining were deduced by sequencing
of the breakpoint junctions of the joined products. Therefore,
we were able to determine the in vivo contribution of each
protein to NHEJ by depleting or inhibiting each factor and
subsequently examining its effect on the efficiency and mode of
joining.
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NHEJ efficiency of chromosomal DSBs with incompatible
DNA ends
To monitor NHEJ efficiency of chromosomal DSBs with
incompatible DNA ends in vivo, we employed a recently described
cell-based assay system (Figure 1A) [14]. Briefly, a repair
substrate containing two I-SceI sites was integrated into the
chromosomal DNA of H1299 human lung cancer cells. NHEJ of
two broken DNA ends generated by I-SceI endonuclease digestion
results in the deletion of the HSV-TK (HSV-thymidine kinase)
open reading frame and leads to the production of a transcript that
enables the translation of enhanced green fluorescent protein
(eGFP) instead of the HSV-TK protein. Therefore, the level of
NHEJ activity in living cells can be evaluated by the proportion of
eGFP-positive cells. The two DNA ends produced on chromo-
somal DNA are incompatible (see Figure 2B) since the two I-SceI
sites were integrated in opposite directions (Figure 1A) and are
predicted to be joined by NHEJ, which may include the end
resection and gap filling steps.
We examined the NHEJ efficiency of cells with defects in each
of the NHEJ steps by disrupting the function of the following
factors: KU80 and DNA-PKcs (synapsis), Artemis (DNA end
resection), POLl and POLm (gap filling), and LIG4 (ligation).
KU80, Artemis, LIG4, POLl and POLm were depleted by RNAi
with similar efficiency (Table S1). DNA-PKcs was impaired by a
50 mM concentration of NU7026, a specific DNA-PKcs inhibitor
previously shown to induce radiosensitization of cancer cells
[14,15,16]. siRNA-mediated depletion or drug-mediated inhibi-
tion of the NHEJ factors significantly decreased the GFP-positive
cell fractions (Figure 1B, 1C, Figure S1). In contrast, depletion
of RAD52, which is involved in homology-mediated repair [2], did
not cause such a reduction. Thus, not only the proteins involved in
the core steps of NHEJ (synapsis and ligation) but also those
involved in DNA end processing (DNA end resection and gap
filling) affect end joining efficiency. Particularly, the depletion of
Artemis and LIG4 led to a drastic reduction in end joining,
demonstrating their important contribution to NHEJ in vivo.
NHEJ modes of incompatible DNA ends
To deduce the mode of end joining from the nucleotide
sequences of the breakpoint junctions, joined products from cells
with/without impairment of NHEJ proteins were cloned, PCR
amplified, size fractionated and sequenced. Three major recurrent
types of products (Types I–III) were observed, as well as several
other types. The 351 bp Type I product was the predominant
form detected in cells transfected with non-targeting siRNA
(siCTR) or DMSO (solvent treatment) (Figure 2A–C). This
product was deduced to be formed by the joining of the DNA
ends, which is accompanied with a two base resection at one DNA
end and followed by gap filling and ligation (Figure 3A).
Fractions of formed products were significantly (P,0.05 by
exact test) affected by the impairment of KU80 or DNA-PKcs
(NU7026 treatment) but not by that of Artemis, LIG4, POLl or
POLm (Table S2). Notably, smaller sized products, specifically
Type II (350 bp) and Type III (348 bp), were predominant in
Figure 1. End-joining efficiency is reduced when NHEJ factors are impaired. (A) Scheme of the assay. Two I-SceI sites in reverse orientation
are indicated by yellow arrow heads. The locations of the PCR primers used for the amplification of joined products are indicated by the red arrows.
CMV: cytomegalovirus promoter/enhancer; IRES: internal ribosome entry site; pA: polyA signal. (B, C) siRNA- or inhibitor-mediated impairment of
NHEJ proteins reduces NHEJ efficiency. (B) The results obtained 48 hr after the transfection of the I-SceI expression plasmid are shown. The proportion
of eGFP-positive cells treated with siRNA or NU7026 (50 uM) is expressed as a ratio of values from siRNA-treated cells versus cells treated with non-
targeting siRNA (siCTR) or DMSO. (C) The results of immunoblot analysis.
doi:10.1371/journal.pone.0028756.g001
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junctions. The sizes of Type I–III products are shown on top. (B, C) Nucleotide sequences of the breakpoint junctions from NHEJ-impaired cells. (B)
The sequences of the breakpoint junctions with the clone number and product type. The structure of the DNA ends generated by I-SceI is shown in
the rectangle. (C) Type I, II and III products according to NHEJ protein impairment (shown as ratios after removing ‘‘Del.6bp’’ and ‘‘Other’’ products).
doi:10.1371/journal.pone.0028756.g002
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cells (Figure 2A–C). Type II and Type III products exhibited the
loss of 1 and 3 more base pairs than Type I products. This result is
consistent with previous results showing that KU70/KU80 and
DNA-PKcs play a major role in synapsis, since the Type II and III
products were likely formed by joining using 2 bp microhomology,
instead of synapsis, followed by the resection of one and two bases
at both DNA ends, respectively (Figure 3B–C).
In Artemis- or LIG4-depleted cells, the spectrum of formed
products did not differ significantly from that of cells transfected
with non-targeting siRNA (Figure 2A–C), which is consistent
with the fact that end resection and ligation were common among
all three types of products (Figure 3). The results were also
consistent with our previous result showing that Artemis or LIG4
depletion resulted in a stronger reduction of joining efficiency than
the depletion of other NHEJ factors (Figure 1B).
In either POLl- or POLm-depleted cells, fractions of formed
products also did not differ significantly from those in cells
transfected with non-targeting siRNA. However, POLl and
POLm double depletion caused a significant difference in the
fraction of products (P=5.2610
26 by exact test), with Type III
(348 bp) products being the predominant form detected. This type
of product was deduced to be formed without gap filling
(Figure 3C). Therefore, this result strongly indicates that POLl
and POLm play redundant roles in gap filling in NHEJ.
Discussion
Here, we showed that the impairment of not only synapsis and
ligation factors but also DNA end resection and gap filling factors
decreased the efficiency of end joining in our cell-based assay
system. Previously, the molecular mechanism of incompatible
DNA end joining, including the DNA end processing steps, had
been studied only using reconstitution experiments in vitro.
Therefore, we have shown for the first time in vivo that all steps
of NHEJ (synapsis, ligation, end resection and gap filling)
contribute to efficient incompatible DNA end joining. The
depletion of Artemis or LIG4 led to a greater reduction in joining
efficiency than that of other factors. DNA end resection is an
inevitable event for the joining of incompatible DNA ends.
Therefore, DNA end resection factors may be necessary for
efficient end joining in addition to ligation proteins. Impairment of
DNA-PKcs by NU7026 treatment resulted in a strong inhibition
of end joining, while siRNA-mediated DNA-PKcs depletion also
led to a reduction in joining efficiency to the same degree as
Artemis depletion did (data not shown). Interestingly, DNA-PKcs
was reported to be required for the nuclease activity of Artemis
[17]. Therefore, the strong inhibitory effect of DNA-PKcs
impairment on joining efficiency might be due to its role in
inhibiting DNA end resection.
We showed that the impairment of synapsis factors KU80 and
DNA-PKcs led to end joining with more DNA end resection in
human cells, consistent with the previous study involving rodent
cells [18]. siRNA-mediated depletion of KU80 was inferred to
impair the KU70/KU80 complex also by de-stabilizing KU70
protein [19]. KU70/KU80 forms a synapsis complex with DNA-
PKcs, which brings both DNA ends together, and the incompat-
ible DNAs with flap ends are subsequently processed by end
resection and gap filling proteins to generate compatible DNA
ends [20,21]. An in vitro reconstitution study indicated that, in the
Figure 3. Deduced NHEJ process for the formation of joint products. (A) Type I products are formed by joining, which is accompanied with
the resection of two bases at one DNA end, followed by gap filling and ligation. (B) Type II products are formed by joining, which is accompanied by
the resection of one base at both DNA ends, followed by gap filling and ligation. (C) Type III products are formed by joining, which is accompanied by
the resection of two bases at both DNA ends, followed by ligation. The type I product is formed predominantly in the presence of synapsis proteins.
Type II and III products are predominantly formed in the absence of synapsis proteins. Hydrogen bonds are likely used to anneal the DNA ends
(green). Type III products are formed via the annealing of DNA ends using a two base homology pair without gap filling, and are thus a major product
formed in the absence of gap-filling proteins POLl and POLm.
doi:10.1371/journal.pone.0028756.g003
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more hydrogen bonds (two or more base pairs) [12]. Types II and
III products were likely formed through the annealing of DNA
ends by four hydrogen bonds using 2 bp micro-homology, and the
impairment of KU80 and DNA-PKcs led to a predominance of
Type II and Type III product formation. Thus, our results indicate
that a synapsis-independent microhomology-mediated joining
occurs in vivo, as previously suggested by the in vitro data.
Our study indicates that the impairment of gap filling factors
POLl and POLm also affect the mode of joining. Depletion of
POLl and POLm together, but not individually, primarily resulted
in Type III product formation; thus, the incompatible DNA ends
were likely processed to generate compatible ends without gaps.
Previous in vitro studies have indicated the significance of POLl
and POLm in incompatible end joining [22,23]. Particularly, one
study using a reconstitution system in vitro clearly showed that
POLl and POLm contributed co-operatively, but not competi-
tively, to gap filling in the joining of incompatible DNA ends [12].
Our result indicates that POLl and POLm contribute redundantly
to the gap filling process in vivo, which is consistent with the above
mentioned studies in vitro. We demonstrated here that the mode of
joining incompatible DNA ends is determined not only by synapsis
factors but also by gap filling factors. To the best of our knowledge,
this is the first report demonstrating the redundant contribution of
POLl and POLm to NHEJ in vivo. Interestingly, POLm has been
suggested to contribute not only to gap-filling but also to end-
bridging [23]. Therefore, reduction in joining efficiency following
POLl and POLm depletion might be also due to the loss of end-
bridging activity, which is an issue that will be investigated in
future studies.
The in vivo assay system used here was useful for the analysis of
the molecular mechanisms of incompatibleDNAend joining.In the
presentstudy,onlyrepresentativeproteinswereanalyzed.However,
other DNA polymerases, such as POL b, are also suggested to be
involved in gap filling in in vitro experiments [12,24]. In addition,
chromatin remodelers, such as covalent remodelers (histone
acetyltransferases, CBP/p300 and TIP60; and histone deacetylases,
HDAC1 and HDAC2) and non-covalent ATPase dependent
remodelers (SWI/SNF complex and ACF complex proteins) have
been also been reported to participate in this process
[14,25,26,27,28]. A comprehensive depletion analyses of each of
those genes, individually and in combination, will elucidate the
molecular mechanisms of joining of incompatible DNA ends. A
potential limitation of the present study is that only a single type of
incompatible end was examined for joining. In fact, depending on
the composition of incompatible DNA ends, POLl and POLm have
been suggested to differentially contribute to the joining of
incompatible ends [24,29], although no difference between POLl
and POLm in this respect was observed in this study. Therefore,
analyses of the joining of several types of DNA ends will further
provide us with valid and detailed information about the individual
contributions of POLl and POLm to end-joining.
Finally, our study defined both the core and non-core DNA end
processing NHEJ factors that are responsible for NHEJ activity and
modeselection.Particularly,abrogationofnotonlysynapsisbutalso
gap filling factors primarily resulted in microhomology-mediated
end joining. This type of joining is representative of an illegitimate
repair pathway resulting in the loss of nucleotides at DSB ends and
is thought to underlie genome instability in cancer cells, since
breakpoint junctions of chromosomal interstitial deletions and
translocations in cancer cells frequently retain traces of micro-
homology-mediated joining [30,31,32]. Large amounts of DSBs
have been shown to occur in pre-malignant cells for human lung
and other cancers [33,34]. Therefore, such cells perform DSB
repair as a way to survive from high levels of DNA damage. The
accumulation of genetic alterations during carcinogenesis may be a
result of the limited amount of synapsis and gap filling factors. In
addition, NHEJ activity was significantly inhibited by the depletion
of ligation and synapsis factors. Inhibitors of DNA-PKcs kinase
activity sensitize cancer cells to IR and are awaiting evaluation for
clinical application as a sensitizer in radiotherapy [35]. Inhibitors of
proteins involved in the ligation and end resection steps might also
be useful as radiosensitizers in cancer therapy.
Methods
NHEJ assay
H1299dA3-1#1, a clone of H1299 human lung cancer cells
(obtained from Dr. John D. Minna of UT Southwestern Medical
Center), stably carries the IRES-TK-EGFP DNA within their
genome [14]. NHEJ assay was performed as described in [14].
Briefly, pCBASce plasmid (I-SceI expression plasmid) DNA
(0.8 mg) was introduced into 7.5610
4 of H1299dA3-1#1 cells
per well in a 24-well plate by transfection with Lipofectamine 2000
reagent (Invitrogen, Carlsbad, CA). For FACS analysis, cells were
harvested by trypsinization, washed with PBS, and applied to a
FACS Calibur cytometer (Beckton Dickinson, Franklin Lakes, NJ).
Fractions of eGFP positive cells were determined by three
independent analyses and were expressed as means +/2 standard
deviations. To examine the effect of siRNAs on DNA joining, cells
were subjected to the NHEJ assay and western blot analysis
48 hours after siRNA transfection. siRNAs were transfected at a
concentration of 50 nM using Lipofectamine RNA MAX
(Invitrogen). To examine the effect of NU7026 (50 mM) (Sigma,
St Louis, MO) on NHEJ, either NU7026 or DMSO was added at
the time of I-SceI introduction until the samples were collected for
analysis. A representative result of at least two independent
experiments is shown for each depletion/inhibition.
siRNA-mediated gene knock down
The following siRNA duplexes were purchased from Dharma-
con (Lafayette, CO) or Qiagen (Valencia, CA): siCTR (D-001810-
01), KU80 (J-010491-05), Artemis (SI00133945), POLl (J-
008746-05), POLm (J-010035-09), LIG4 (J-004254-09) and
RAD52 (J-011760-05). siRNAs were transfected into 2610
4 cells
in a 12-well plate at a final concentration of 50 nM using
lipofectamine RNA MAX (Invitrogen). At 72 hours after siRNA
transfection, the cells were subjected to the NHEJ assay as well as
western blot analysis to examine knockdown efficiency. Protein
levels in siRNA-treated cells were examined by western blot
analysis using specific antibodies. Antibodies used in this study
were purchased from Sigma (a-tubulin: T6199), Bethyl Labora-
tories (Artemis: A300-234A), Santa Cruz Biotechnology (POLl:
sc21531; POLm: sc27769; KU80: sc9034; LIG4: sc11750), and
Cell Signaling Technology (RAD52: #3425).
Analysis of breakpoint junctions
DNA fragments containing breakpoint junctions were amplified
by PCR using 10 ng of genomic DNAs obtained from H1299dA3-
1#1 cells subjected to NHEJ assay as templates. To examine the
size of the fragments, PCR was performed with a set of primers,
BP-F* (FITC-labeled) and maxGFP-R2, and the PCR products
were directly separated by electrophoresis using an ABI 3700
Sequence Analyzer (Applied Biosystems, Foster City, CA) and
analyzed by the Gene Scan software. To determine the sequences
of the breakpoint junctions, PCR products amplified by BP-F1 and
maxGFP-R2 were subcloned into the pGEM-T vector (Promega,
Madison, WI) by TA-cloning and were sequenced using the ABI
Essential Factors for Incompatible DNA End Joining
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Biosystems). Nucleotide sequences of the BP-F1 and maxGFP-R2
primers were previously described [14]. The sequences of
breakpoint junctions were determined for each depletion/
inhibition by direct sequencing of colony-PCR products.
Supporting Information
Figure S1 eGFP-positive cells (boxed) assessed by FACS analysis
48 hours after an I-SceI expression plasmid transfection.
(PDF)
Table S1 Knockdown efficiency.
(PDF)
Table S2 Joined products resulting from the impairment of
NHEJ proteins.
(PDF)
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